Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanchang UniversityNo recent work listed

Jiefeng Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2481-6875; OpenAlex author ID A5059112369. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 2 papers

Papers 4

  1. FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression. First author DOI 10.1038/s41419-022-04960-0↗
  2. Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis. Co-author DOI 10.3389/fphar.2022.1025618↗
  3. A signature of 18 immune-related gene pairs to predict the prognosis of pancreatic cancer patients. Co-author DOI 10.1002/iid3.363↗
  4. Expression Profile of GINS Complex Predicts the Prognosis of Pancreatic Cancer Patients. Co-author DOI 10.2147/ott.s275649↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fanqin Bu · 4 shared papers, 2020–2022 · strength 0.54
  2. Rongfa Yuan · 2 shared papers, 2022 · strength 0.31
  3. Chen Huan Luo · 2 shared papers, 2020–2022 · strength 0.24
  4. Jinfeng Zhu · 2 shared papers, 2020–2022 · strength 0.24
  5. Jun Huang · 2 shared papers, 2020 · strength 0.23
  6. Zhengming Zhu · 1 shared paper, 2022 · strength 0.17
  7. Leifeng Chen · 1 shared paper, 2022 · strength 0.13
  8. Xin Yu · 1 shared paper, 2022 · strength 0.13
  9. Han Nie · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.